Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Lactobacillus johnsonii is a probiotic bacterium that has been investigated for its potential role in supporting or treating Inflammatory Bowel Disorders (IBD), including Crohn’s disease and ulcerative colitis. The scientific evidence for its efficacy is limited but growing. Several animal studies have demonstrated that L. johnsonii administration can modulate gut microbiota, enhance mucosal barrier function, and reduce markers of intestinal inflammation. For example, studies in mouse models of colitis have shown that L. johnsonii can decrease levels of pro-inflammatory cytokines and improve histological outcomes in the colon.

Human data, however, are sparse. A few small clinical trials in patients with IBD have evaluated L. johnsonii, often as part of a probiotic mixture rather than a single strain. Some of these studies suggest a potential benefit in maintaining remission or reducing symptoms, but results are inconsistent and often underpowered. Notably, a pilot study (Prisciandaro et al., Inflamm Bowel Dis, 2004) found that L. johnsonii supplementation reduced intestinal inflammation in humans, but larger, well-controlled trials are lacking.

In summary, while preclinical studies provide a scientific rationale for the use of L. johnsonii in IBD, clinical evidence remains preliminary. More robust human trials are needed to confirm its efficacy and determine appropriate dosing and formulations.

More about Lactobacillus johnsonii
More about Inflammatory Bowel Disorders

Other ingredients used for Inflammatory Bowel Disorders

Other health conditions supported by Lactobacillus johnsonii

Products containing Lactobacillus johnsonii